Clinical trial · Interventional
THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence
Pilot Study of Positive Affect Training for Endocrine Therapy Medication Adherence
NCT06388304CI-TRIAL-00101314THRIVEcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to pilot and refine an online behavioral intervention based on Positive Affect Training (PAT) that aims to increase positive emotional attitudes and decrease negative emotional attitudes toward endocrine therapy (ET, i.e., anti-hormonal medication) and to increase positive affect and decrease negative affect more generally, among post-treatment breast cancer survivors who are prescribed ET to prevent recurrence of breast cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| DCIS | Breast Ductal Carcinoma In Situ | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| THRIVE Online PAT Program | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Online Program
- description
- Online program
- interventionNames
- Behavioral: THRIVE Online PAT Program
Primary outcomes (3)
- measure
- Acceptability of THRIVE intervention (AIM)
- timeFrame
- 1 week post-intervention
- description
- Acceptability of Implementation Measure (Weimer et al., 2017)
- measure
- Feasibility of THRIVE intervention
- timeFrame
- 1 week post-intervention
- description
- Feasibility of Intervention Measure (Weimer et al., 2017)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * hormone receptor-positive breast cancer stages 0-3 * have finished primary treatment (chemotherapy/radiation/surgery) * are prescribed endocrine therapy (ET) currently or within the last two years * score above specified cut off (range, 0-10) on any of three questions: 1. How upset are you by having to take anti-hormonal therapy 2. How bothered are you by the side effects? 3. How difficult is it for you to take your anti-hormonal medication every day? * have internet access to complete online assessments and intervention components or agree to use and return a study wifi-activated iPad. Exclusion Criteria: * metastatic disease * Individuals who are unable to interact with the intervention as needed. This includes those who are extremely visually impaired to the degree that they cannot see the screen and interact as required and individuals who cannot read and/or write in English. This is due to the nature of the intervention itself. If a participant is unable to interact with THRIVE as required, they are unlikely to benefit from the intervention or offer insightful feedback that can be used in refining the program.
References
Publications (4)
- BACKGROUNDCraske MG, Meuret AE, Ritz T, Treanor M, Dour H, Rosenfield D. Positive affect treatment for depression and anxiety: A randomized clinical trial for a core feature of anhedonia. J Consult Clin Psychol. 2019 May;87(5):457-471. doi: 10.1037/ccp0000396. PMID 30998048
- BACKGROUNDCraske MG, Meuret AE, Ritz T, Treanor M, Dour HJ. Treatment for Anhedonia: A Neuroscience Driven Approach. Depress Anxiety. 2016 Oct;33(10):927-938. doi: 10.1002/da.22490. PMID 27699943
- BACKGROUNDCraske MG, Meuret AE, Echiverri-Cohen A, Rosenfield D, Ritz T. Positive affect treatment targets reward sensitivity: A randomized controlled trial. J Consult Clin Psychol. 2023 Jun;91(6):350-366. doi: 10.1037/ccp0000805. Epub 2023 Mar 9. PMID 36892884
- BACKGROUNDArch JJ, Crespi CM, Levin ME, Genung SR, Nealis M, Mitchell JL, Bright EE, Albright K, Magidson JF, Stanton AL. Randomized Controlled Pilot Trial of a Low-Touch Remotely-Delivered Values Intervention to Promote Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors. Ann Behav Med. 2022 Aug 2;56(8):856-871. doi: 10.1093/abm/kaab118. PMID 35323853